Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial

Reuters

Dec 10, 2025

<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial

Kazia Therapeutics Limited has announced new clinical and translational findings demonstrating the activity of its brain-penetrant dual PI3K/mTOR inhibitor, paxalisib, across multiple advanced breast cancer populations, including triple-negative breast cancer (TNBC) and HER2-positive metastatic breast cancer. The results were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Highlights include a 76% reduction in tumor volume in the first TNBC patient, significant decreases in circulating tumor cell (CTC) clusters, and evidence of immune system reinvigoration. Preliminary ex-vivo data in HER2-positive patients showed similar immune effects and reductions in CTCs. The findings suggest that paxalisib may address metastatic mechanisms not targeted by current therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43262) on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590837587"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590837587\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590837587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590837587","market":"fut","top_or_hot":-1,"title":"Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced new clinical and translational findings demonstrating the activity of its brain-penetrant dual PI3K/mTOR inhibitor, paxalisib, across multiple advanced breast cancer populations, including triple-negative breast cancer (TNBC) and HER2-positive metastatic breast cancer. The results were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Highlights include a 76% reduction in tumor volume in the first TNBC patient, significant decreases in circulating tumor cell (CTC) clusters, and evidence of immune system reinvigoration. Preliminary ex-vivo data in HER2-positive patients showed similar immune effects and reductions in CTCs. The findings suggest that paxalisib may address metastatic mechanisms not targeted by current therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43262) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced new clinical and translational findings demonstrating the activity of its brain-penetrant dual PI3K/mTOR inhibitor, paxalisib, across multiple advanced breast cancer populations, including triple-negative breast cancer (TNBC) and HER2-positive metastatic breast cancer. The results were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Highlights include a 76% reduction in tumor volume in the first TNBC patient, significant decreases in circulating tumor cell (CTC) clusters, and evidence of immune system reinvigoration. Preliminary ex-vivo data in HER2-positive patients showed similar immune effects and reductions in CTCs. The findings suggest that paxalisib may address metastatic mechanisms not targeted by current therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43262) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZIA","symbol_name":"Kazia Therapeutics Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL5L8hvJ:1","article_id":"2590837587","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590837587","pubTimestamp":1765371654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kazia Therapeutics Limited has announced new clinical and translational findings demonstrating the activity of its brain-penetrant dual PI3K/mTOR inhibitor, paxalisib, across multiple advanced breast cancer populations, including triple-negative breast cancer  and HER2-positive metastatic breast cancer. The results were presented at the 2025 San Antonio Breast Cancer Symposium . Highlights include a 76% reduction in tumor volume in the first TNBC patient, significant decreases in circulating tumor cell  clusters, and evidence of immune system reinvigoration. Preliminary ex-vivo data in HER2-positive patients showed similar immune effects and reductions in CTCs. The findings suggest that paxalisib may address metastatic mechanisms not targeted by current therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZIA":"Kazia Therapeutics Limited","BK4139":"生物科技"},"translate_title":"Kazia Therapeutics报告Paxalisib在晚期乳腺癌试验中显示肿瘤缩小和免疫重振","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial\n    \n\nKazia Therapeutics Limited has announced new clinical and translational findings demonstrating the activity of its brain-penetrant dual PI3K/mTOR inhibitor, paxalisib, across multiple advanced breast cancer populations, including triple-negative breast cancer (TNBC) and HER2-positive metastatic breast cancer. The results were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Highlights include a 76% reduction in tumor volume in the first TNBC patient, significant decreases in circulating tumor cell (CTC) clusters, and evidence of immune system reinvigoration. Preliminary ex-vivo data in HER2-positive patients showed similar immune effects and reductions in CTCs. The findings suggest that paxalisib may address metastatic mechanisms not targeted by current therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43262) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}